{"name":"Octapharma","slug":"octapharma","ticker":"","exchange":"","domain":"octapharma.com","description":"","hq":"Lachen","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-08-26","label":"Glassia Phase 3 readout (Alpha1-Antitrypsin Deficiency)","drug":"Glassia","drugSlug":"glassia","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-02-01","label":"Glassia Phase 3 readout (Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency)","drug":"Glassia","drugSlug":"glassia","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"oncology","drugs":[{"name":"NewGam","genericName":"NewGam","slug":"newgam","indication":"Other","status":"phase_3"},{"name":"Octaplex","genericName":"Octaplex","slug":"octaplex","indication":"Other","status":"phase_3"},{"name":"Fibryga","genericName":"Fibryga","slug":"fibryga","indication":"Other","status":"discontinued"},{"name":"Gammanorm","genericName":"Gammanorm","slug":"gammanorm","indication":"Other","status":"marketed"},{"name":"Glassia","genericName":"Glassia","slug":"glassia","indication":"Other","status":"discontinued"},{"name":"OCTA-C1-INH","genericName":"OCTA-C1-INH","slug":"octa-c1-inh","indication":"Hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction","status":"phase_3"},{"name":"Panzyga","genericName":"Panzyga","slug":"panzyga","indication":"Other","status":"marketed"},{"name":"Von Willebrand Factor-Containing Product","genericName":"Von Willebrand Factor-Containing Product","slug":"von-willebrand-factor-containing-product","indication":"Other","status":"phase_2"},{"name":"Atenativ","genericName":"Atenativ","slug":"atenativ","indication":"Other","status":"marketed"},{"name":"Balfaxar","genericName":"Balfaxar","slug":"balfaxar","indication":"Other","status":"marketed"},{"name":"Eqwilate","genericName":"Eqwilate","slug":"eqwilate","indication":"Other","status":"phase_2"},{"name":"Newnorm","genericName":"Newnorm","slug":"newnorm","indication":"Other","status":"phase_3"},{"name":"Nuwiq","genericName":"SIMOCTOCOG ALFA","slug":"simoctocog-alfa","indication":"Factor VIII deficiency","status":"marketed"},{"name":"Octafibrin","genericName":"Octafibrin","slug":"octafibrin","indication":"Other","status":"phase_3"},{"name":"Octagam IVIG 5% or 10%","genericName":"Octagam IVIG 5% or 10%","slug":"octagam-ivig-5-or-10","indication":"Other","status":"phase_2"},{"name":"Octanorm","genericName":"Octanorm","slug":"octanorm","indication":"Other","status":"discontinued"},{"name":"Octaplas LG","genericName":"Octaplas LG","slug":"octaplas-lg","indication":"Other","status":"phase_2"},{"name":"Uniplas","genericName":"Uniplas","slug":"uniplas","indication":"Other","status":"discontinued"},{"name":"recombinant Factor VIII","genericName":"recombinant Factor VIII","slug":"recombinant-factor-viii","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Antithrombin III","genericName":"Antithrombin III","slug":"antithrombin-iii","indication":"Antithrombin III deficiency (congenital or acquired) for prevention and treatment of thromboembolism","status":"marketed"},{"name":"Human plasma derived antithrombin","genericName":"Human plasma derived antithrombin","slug":"human-plasma-derived-antithrombin","indication":"Antithrombin deficiency (congenital or acquired)","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"human VWF/FVIII concentrate","genericName":"human VWF/FVIII concentrate","slug":"human-vwf-fviii-concentrate","indication":"Hemophilia A","status":"phase_3"},{"name":"Human cl rhFVIII","genericName":"Human cl rhFVIII","slug":"human-cl-rhfviii","indication":"Hemophilia A (congenital Factor VIII deficiency)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Panzyga, 10% Intravenous Solution","genericName":"Panzyga, 10% Intravenous Solution","slug":"panzyga-10-intravenous-solution","indication":"Primary immunodeficiency disorders","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"octanorm 16.5%","genericName":"octanorm 16.5%","slug":"octanorm-16-5","indication":"Hypoproteinemia and hypovolemia in acute blood loss or severe burns","status":"phase_3"}]}],"pipeline":[{"name":"NewGam","genericName":"NewGam","slug":"newgam","phase":"phase_3","mechanism":"Provides passive immunity and immune modulation through polyspecific human immunoglobulins that interact with Fc receptors and complement components.","indications":[],"catalyst":""},{"name":"Octaplex","genericName":"Octaplex","slug":"octaplex","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antithrombin III","genericName":"Antithrombin III","slug":"antithrombin-iii","phase":"marketed","mechanism":"Antithrombin III is a natural anticoagulant protein that inhibits blood clotting factors (thrombin and factor Xa) to prevent pathological thrombosis.","indications":["Antithrombin III deficiency (congenital or acquired) for prevention and treatment of thromboembolism","Perioperative thromboembolism prophylaxis in patients with antithrombin deficiency"],"catalyst":""},{"name":"Fibryga","genericName":"Fibryga","slug":"fibryga","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Gammanorm","genericName":"Gammanorm","slug":"gammanorm","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glassia","genericName":"Glassia","slug":"glassia","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OCTA-C1-INH","genericName":"OCTA-C1-INH","slug":"octa-c1-inh","phase":"phase_3","mechanism":"OCTA-C1-INH is a recombinant C1-esterase inhibitor that replaces or augments deficient or dysfunctional C1-inhibitor protein to prevent excessive complement and contact system activation.","indications":["Hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction"],"catalyst":""},{"name":"Panzyga","genericName":"Panzyga","slug":"panzyga","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Panzyga, 10% Intravenous Solution","genericName":"Panzyga, 10% Intravenous Solution","slug":"panzyga-10-intravenous-solution","phase":"phase_3","mechanism":"Panzyga is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and reduce inflammation.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"Von Willebrand Factor-Containing Product","genericName":"Von Willebrand Factor-Containing Product","slug":"von-willebrand-factor-containing-product","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"human VWF/FVIII concentrate","genericName":"human VWF/FVIII concentrate","slug":"human-vwf-fviii-concentrate","phase":"phase_3","mechanism":"Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A.","indications":["Hemophilia A","Surgery in patients with hemophilia A"],"catalyst":""},{"name":"Atenativ","genericName":"Atenativ","slug":"atenativ","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Balfaxar","genericName":"Balfaxar","slug":"balfaxar","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eqwilate","genericName":"Eqwilate","slug":"eqwilate","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Human cl rhFVIII","genericName":"Human cl rhFVIII","slug":"human-cl-rhfviii","phase":"phase_3","mechanism":"Human cl rhFVIII is a recombinant human Factor VIII that replaces deficient or dysfunctional clotting factor VIII to restore blood coagulation in hemophilia A patients.","indications":["Hemophilia A (congenital Factor VIII deficiency)"],"catalyst":""},{"name":"Human plasma derived antithrombin","genericName":"Human plasma derived antithrombin","slug":"human-plasma-derived-antithrombin","phase":"phase_3","mechanism":"Antithrombin is a natural anticoagulant protein that inhibits blood clotting factors to prevent thrombosis.","indications":["Antithrombin deficiency (congenital or acquired)","Thromboembolism prevention and treatment in high-risk patients"],"catalyst":""},{"name":"Newnorm","genericName":"Newnorm","slug":"newnorm","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Nuwiq","genericName":"SIMOCTOCOG ALFA","slug":"simoctocog-alfa","phase":"marketed","mechanism":"Recombinant protein","indications":["Factor VIII deficiency","Hereditary factor VIII deficiency disease"],"catalyst":""},{"name":"Octafibrin","genericName":"Octafibrin","slug":"octafibrin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Octagam IVIG 5% or 10%","genericName":"Octagam IVIG 5% or 10%","slug":"octagam-ivig-5-or-10","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Octanorm","genericName":"Octanorm","slug":"octanorm","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Octaplas LG","genericName":"Octaplas LG","slug":"octaplas-lg","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Uniplas","genericName":"Uniplas","slug":"uniplas","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"octanorm 16.5%","genericName":"octanorm 16.5%","slug":"octanorm-16-5","phase":"phase_3","mechanism":"Octanorm 16.5% is a human albumin solution that restores intravascular oncotic pressure and maintains plasma volume in patients with hypoproteinemia or acute blood loss.","indications":["Hypoproteinemia and hypovolemia in acute blood loss or severe burns","Plasma volume expansion in critical care settings"],"catalyst":""},{"name":"recombinant Factor VIII","genericName":"recombinant Factor VIII","slug":"recombinant-factor-viii","phase":"phase_3","mechanism":"Replaces deficient or absent Factor VIII protein to restore normal blood coagulation cascade function in hemophilia A patients.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOamRjWlV4QWFFejhWZnJIUjJienZjaW5aWER4a21VYl9EMzFaSmEtNmltX3hFZTU2Nmg3VU4tSXBvT0QyTGN5THdnN25PTUczdEhZd2YwWVFHclNnZlZLWlJ0QnFQbmltNGlYWW5RMDM2ZGZ4WnZ1UHhrdUZQamdKS1VlcFItNzR6VmdHZVVsdlh6OGRjMkJxeElRZUNoaWtsVkFKeV9XMjBfMHJmUkE?oc=5","date":"2026-02-25","type":"pipeline","source":"BioSpace","summary":"Abram Scientific Secures $11.75M Series A Funding Led by Octapharma AG - BioSpace","headline":"Abram Scientific Secures $11.75M Series A Funding Led by Octapharma AG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQYlFVWTZ3Y0JMSngxQ1RJQnBtaDB4MHBkSjJRTHc4NjVlM0F1bGI0ckdjWkRYX0U1aXNJcGR5MWRCM180MkttVkNGVHZPYzdmM0I0M2VodGF2WUtYYU9ORUthRWYtbTNTVGJGYnZrN3JISjkyX3lQSVZGaTZ2TE5aOUdoQUV0MDhnbGs5SnBodjJYeTgzcXpUenZQS0VyUWlNMXlNMlR0akUxZlBGam1keXE5SVQ?oc=5","date":"2026-02-11","type":"pipeline","source":"WHEC.com","summary":"Police: Victim and suspect taken to local hospitals after stabbing at Octapharma Plasma - WHEC.com","headline":"Police: Victim and suspect taken to local hospitals after stabbing at Octapharma Plasma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNUUFNUTNIc18yWl9tck5SQUZnNWthRm9IM2tyLXBxRzNWaC1pWHpSWmVzbzZhQVVEM1M1MWp3dW81NW1lUm1kWm4xYXpXdWFsT25pYU5yYzhPUDFLemVXUUdIVk56VGFDMWVOdnBuSlUzOFlVSUtsVDVqcVdlVkItVGVuOUYtdS1FTmVhNS1CNEtMdFRxZlE?oc=5","date":"2026-01-08","type":"regulatory","source":"Pharmaceutical Technology","summary":"Octapharma receives FDA approval for new Fibryga formulation in AFD - Pharmaceutical Technology","headline":"Octapharma receives FDA approval for new Fibryga formulation in AFD","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxNVzNBNWFlOENtX1RWYndlemRvMmkxUGhzYjdmZzFkMUZDbGJLSmxxMW56TUFFYi1kb3BzNzRub2N2dTR4S3VwYkl1Z3NpOFoyUWRmS0pnTVNvZzFSbC1xLUZ5ZkxzUVpJc3dzR3lMNzZQdTdMX2p2YWpVZGoxUm1xWERpdk9YbmlKWndYQWNmSjl4MXpiTjh6bS1oMGVXR252S3dNTEhLYmNMcHQ1ZmllQVB1ZlpPVWRXZE0tT1pFZV9ma3NYaEpBQnFQVGI0ajBiYzNfNDgtcU5TUl9SODdudzJwX3VJUDlXUURqTVlRU3V4TXJBSzY3SDIwSV96SmE0aHpORjZLV25ET3FQbXA4?oc=5","date":"2026-01-07","type":"regulatory","source":"prnewswire.com","summary":"FDA Approves New 2-Gram Presentation of Fibryga®, Enhancing Convenience and Precision in Treating Acquired Fibrinogen Deficiency - prnewswire.com","headline":"FDA Approves New 2-Gram Presentation of Fibryga®, Enhancing Convenience and Precision in Treating Acquired Fibrinogen De","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1XTjhzTFhUTlYzcVVvZXVKeGRsVzBQcHZERWVvemU0TTZIXy1Bdk5xd1dqZ0xaRVROdzluNmMyVWlnQ1VkclZUdTFZZy1ubWV3bElrb2xxTUJLZlBfU0RaUTdDMHJYX0I2Wnc?oc=5","date":"2025-10-02","type":"trial","source":"The HIPAA Journal","summary":"$2.55M Settlement Agreed to Resolve Octapharma Plasma Data Breach Lawsuit - The HIPAA Journal","headline":"$2.55M Settlement Agreed to Resolve Octapharma Plasma Data Breach Lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE44cDVGTndMN2I5cWwwOTB2UHRRdUY3bVBkMWc2S2s1RFVPR2poRDQ4RjN2ajRzWEwtOEcxN0hSWDltdzFVandrMEFCNERFM0xCNGR1b1IzT21pQXJNcGdrU0Rpb2NDYmVsNm1sUjFBZFBoYmRvYkxKam0xdw?oc=5","date":"2025-09-25","type":"pipeline","source":"Talk Business & Politics","summary":"Octapharma Plasma opens in Springdale - Talk Business & Politics","headline":"Octapharma Plasma opens in Springdale - Talk Business & Politics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5mcWlGOEtPVXc4TkVHREYxWEIwbmxwdmg3MF9sc0NXdkNQZmRDT3NrbDF0SDNuNmhKU2NUT1RBQTZfWWJTazdFcGtZSjZ3dk1OZ1UweDdsRlNrbnRSLWZ1eGdMRnA2ZU81Vmc?oc=5","date":"2025-09-15","type":"trial","source":"Claim Depot","summary":"Octapharma Plasma agrees to settle data breach class action for $2.55M - Claim Depot","headline":"Octapharma Plasma agrees to settle data breach class action for $2.55M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNNU96UGtQWVpmb3h0bUZyU0NwYlF0RDliajk1bGhMWHI1cEZiOE41TXdWMnNxUnQ1VFJ4M1hKY0ZnZ0VTRnRDdjQ0V0JzM1doaU9kZkhCd1NkcW1IU1hzb1RBN0xoQ1c0NFRpWWZwNndPSUtaVUNMRHRDa3JaRDIzX3ViRnVrQzVTa212UXlMVU1UendVM3RTNlkyX2VxU1JJV1U5TXJIU3hDb1BLYmhObWJhZ2daQmxOVmNZdGxTRFpnUW53am9oWk5fWUkzYUVRLTB2eHFkQTl2TFpWWFlwTFUwUlVtSE1QNlFROENmRDN6YXEwaGxN?oc=5","date":"2025-05-28","type":"trial","source":"prnewswire.com","summary":"Octapharma Releases Results for Phase 3 Superiority Study of Pediatric Acute-onset Neuropsychiatric Syndrome - prnewswire.com","headline":"Octapharma Releases Results for Phase 3 Superiority Study of Pediatric Acute-onset Neuropsychiatric Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOcVVVTUxSanZMSDBLUmhxODJLc3AteHVxZFVOTW1RRmd2Q3VJeEgzX2ZpcldDQTRGajJJa2dYVVI5QXFsVGo2Y1RPU3c0T3hKZDVXc2VfN2FGOVRuVHo2SzltR2NvbGN1Uk84cTFQeEIyZVg4SFdXSDZwLWZqVi1ZOXV3VjhZN3FHUEdCRnVfbmRxczhRVXNUSjFrYzRMeGVsQlZpdjBNd3pOdFR3SDRkbFg0MGgzZjFvSm1tNQ?oc=5","date":"2025-05-20","type":"pipeline","source":"Pharmaceutical Technology","summary":"Next‑Gen Pharma: AI, ML & Digital Twins Converge at AUTOMA+ 2025 - Pharmaceutical Technology","headline":"Next‑Gen Pharma: AI, ML & Digital Twins Converge at AUTOMA+ 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQOHgtQVpzdks1Q3dMVE9ZelhXREtrc0Q5UzlZaUV3c3k3SDBDak9XSml1VGFEX3NkN2tMQk9jQmdUNTFuOFFiallKdEJRVGllQnROOElqN1FmSG1iY2hrdGpUQTNsUDFVamRmOEgyejVDZXVBZUVYcks5Mm9yNmlyYXRBamVWTFdwTVI1N0QwVFNBRHNyTXZDdk11b2tKTUxxWk5OaTFBZGE?oc=5","date":"2025-03-06","type":"pipeline","source":"PharmaTimes","summary":"NHS patients receive UK-donated plasma medicines for first time in 30 years - PharmaTimes","headline":"NHS patients receive UK-donated plasma medicines for first time in 30 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOOXhXT05oempzVXJDN0NmbWpXb1prdGJMM3hsSXdHZmQyVlhSR0MzYTZZY3RDRE56eWE2amFla3VPQnlzQUhhLVFUNXJmeHNRZUREbFQ5MVR2dmF4dXNNdzE0aUd2YUdvaC1EUVl4U0pWWklyQkpldGZRNk1IREswcmNNTE9VSVlXdG56OVJENE5Sd9IBlwFBVV95cUxNU1Z4NUlQaXVwYVFtdE9jYXZ5emwzVUlFakZ1V183ZnMxaE1nZThyTXpKQmVZT0xVUXlFcDRNVV8zaGY5ZVNaV0lkSWdXQ3AtY1FKY0xnb2IydGtkQ0dnZVppM2RGTnJFdnA4aHFvMzcwdVNKamVOQ0xTbU1UVlhTT21mdE4yVVFOZEtaZGFzVXV4OEVMUG5N?oc=5","date":"2024-04-20","type":"pipeline","source":"ABC30 Fresno","summary":"Octapharma Plasma pauses operations at all sites nationwide - ABC30 Fresno","headline":"Octapharma Plasma pauses operations at all sites nationwide - ABC30 Fresno","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPN3ZweXprcGhFMEZMM0E2Vm9FV095V2pZRFlfZGpaSDRDUW1RelBHMWluYTlqRmFIcnAzRDNFMmdNUmRSMGJPV1dEbDR6UzJxQ2VLZEJVVFZQdmFpYll2MHpDWm14Yk5PVWdKb1FnQlIwRWFmUU9fZTZCVUhmX2NtRTZ2UDdwN05sclBTdFVuX0tIeF9PSmdRbGFvUllVU2ZWTFV5amlKcXdZVk9mZXpEclo1X3k0ZnlUaVpxMmZEeldNQQ?oc=5","date":"2024-04-19","type":"pipeline","source":"Cyber Daily","summary":"US firm Octapharma Plasma may have shut down US operations due to ransomware attack - Cyber Daily","headline":"US firm Octapharma Plasma may have shut down US operations due to ransomware attack","sentiment":"neutral"}],"patents":[],"drugCount":25,"phaseCounts":{"phase_3":11,"marketed":6,"discontinued":4,"phase_2":4},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}